Pharmaceutical company Novo Nordisk reduced its financial outlook and reported earnings below analyst expectations, primarily impacted by significant restructuring expenses.
Shareholders have approved Elon Musk’s pay package, which is valued at $1 trillion, marking one of the largest compensation plans in corporate history.
The S&P 500 declined amid growing concerns around job cuts and weak performance in the technology sector.
An AI-chosen stock rose over 30% in the early days of November, highlighting the growing influence of artificial intelligence in investment decisions.
Wolfe Research described recent Supreme Court oral arguments as "negative" for the levies against former President Trump.
Author's summary: Novo Nordisk’s lowered forecast reflects restructuring challenges, while Tesla's massive Musk pay deal and market shifts grab investor attention.